カテゴリー： LP Information, 世界, 部品/材料

世界の子宮平滑筋腫治療薬市場予測 2023年-2029年

◆英語タイトル：Global Uterine Leiomyomata Medication Market Growth 2023-2029

LP Informationが発行した調査報告書（LP23JU2259）◆商品コード：LP23JU2259
◆発行会社（リサーチ会社）：LP Information
◆発行日：2023年5月（※2025年版があります。お問い合わせください。）
◆ページ数：97
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆産業分野：化学＆材料
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥527,040見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥790,560見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,054,080見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の子宮平滑筋腫治療薬市場」は、過去の販売実績から2022年の世界の子宮平滑筋腫治療薬の総販売量を検討し、2023年から2029年の予測される子宮平滑筋腫治療薬の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の子宮平滑筋腫治療薬の市場規模を掲載し、XXX百万米ドル規模の世界の子宮平滑筋腫治療薬市場の詳細な分析を提供します。本インサイトレポートは、世界の子宮平滑筋腫治療薬業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の子宮平滑筋腫治療薬市場における各社の独自のポジションをより深く理解するために、子宮平滑筋腫治療薬製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の子宮平滑筋腫治療薬市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。子宮平滑筋腫治療薬の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。子宮平滑筋腫治療薬の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。子宮平滑筋腫治療薬のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

子宮平滑筋腫治療薬の世界主要メーカーとしては、AbbVie Inc.、 TOLMAR Pharmaceuticals, Inc.、 TerSera Therapeutics LLC.、 Verity Pharmaceuticals、 Arbor Pharmaceuticals、 Ferring Pharmaceuticals、 Pfizerなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の子宮平滑筋腫治療薬市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では子宮平滑筋腫治療薬市場をセグメンテーションし、種類別 (GnRHアゴニスト、トラネキサム酸、NSAID、避妊薬（OC）)、用途別 (経口、注射)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：GnRHアゴニスト、トラネキサム酸、NSAID、避妊薬（OC）

・用途別区分：経口、注射

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の子宮平滑筋腫治療薬市場の10年間の市場状況・展望は？
・世界および地域別に見た子宮平滑筋腫治療薬市場成長の要因は何か？
・子宮平滑筋腫治療薬の市場機会はエンドマーケットの規模によってどのように変化するのか？
・子宮平滑筋腫治療薬のタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：子宮平滑筋腫治療薬の年間販売量2018-2029、地域別現状・将来分析
・子宮平滑筋腫治療薬の種類別セグメント：GnRHアゴニスト、トラネキサム酸、NSAID、避妊薬（OC）
・子宮平滑筋腫治療薬の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・子宮平滑筋腫治療薬の用途別セグメント：経口、注射
・子宮平滑筋腫治療薬の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の子宮平滑筋腫治療薬市場
・企業別のグローバル子宮平滑筋腫治療薬市場データ：2018-2023年の年間販売量、市場シェア
・企業別の子宮平滑筋腫治療薬の年間売上：2018-2023年の売上、市場シェア
・企業別の子宮平滑筋腫治療薬販売価格
・主要企業の子宮平滑筋腫治療薬生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

子宮平滑筋腫治療薬の地域別レビュー
・地域別の子宮平滑筋腫治療薬市場規模2018-2023：年間販売量、売上
・主要国別の子宮平滑筋腫治療薬市場規模2018-2023：年間販売量、売上
・南北アメリカの子宮平滑筋腫治療薬販売の成長
・アジア太平洋の子宮平滑筋腫治療薬販売の成長
・ヨーロッパの子宮平滑筋腫治療薬販売の成長
・中東・アフリカの子宮平滑筋腫治療薬販売の成長

南北アメリカ市場
・南北アメリカの国別の子宮平滑筋腫治療薬販売量、売上（2018-2023）
・南北アメリカの子宮平滑筋腫治療薬の種類別販売量
・南北アメリカの子宮平滑筋腫治療薬の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の子宮平滑筋腫治療薬販売量、売上（2018-2023）
・アジア太平洋の子宮平滑筋腫治療薬の種類別販売量
・アジア太平洋の子宮平滑筋腫治療薬の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の子宮平滑筋腫治療薬販売量、売上（2018-2023）
・ヨーロッパの子宮平滑筋腫治療薬の種類別販売量
・ヨーロッパの子宮平滑筋腫治療薬の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の子宮平滑筋腫治療薬販売量、売上（2018-2023）
・中東・アフリカの子宮平滑筋腫治療薬の種類別販売量
・中東・アフリカの子宮平滑筋腫治療薬の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・子宮平滑筋腫治療薬の製造コスト構造分析
・子宮平滑筋腫治療薬の製造プロセス分析
・子宮平滑筋腫治療薬の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・子宮平滑筋腫治療薬の主要なグローバル販売業者
・子宮平滑筋腫治療薬の主要なグローバル顧客

地域別の子宮平滑筋腫治療薬市場予測レビュー
・地域別の子宮平滑筋腫治療薬市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・子宮平滑筋腫治療薬の種類別市場規模予測
・子宮平滑筋腫治療薬の用途別市場規模予測

主要企業分析
AbbVie Inc.、 TOLMAR Pharmaceuticals, Inc.、 TerSera Therapeutics LLC.、 Verity Pharmaceuticals、 Arbor Pharmaceuticals、 Ferring Pharmaceuticals、 Pfizer
・企業情報
・子宮平滑筋腫治療薬製品
・子宮平滑筋腫治療薬販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

LPI (LP Information)’ newest research report, the “Uterine Leiomyomata Medication Industry Forecast” looks at past sales and reviews total world Uterine Leiomyomata Medication sales in 2022, providing a comprehensive analysis by region and market sector of projected Uterine Leiomyomata Medication sales for 2023 through 2029. With Uterine Leiomyomata Medication sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Uterine Leiomyomata Medication industry.
This Insight Report provides a comprehensive analysis of the global Uterine Leiomyomata Medication landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Uterine Leiomyomata Medication portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Uterine Leiomyomata Medication market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Uterine Leiomyomata Medication and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Uterine Leiomyomata Medication.
The global Uterine Leiomyomata Medication market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Uterine Leiomyomata Medication is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Uterine Leiomyomata Medication is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Uterine Leiomyomata Medication is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Uterine Leiomyomata Medication players cover AbbVie Inc., TOLMAR Pharmaceuticals, Inc., TerSera Therapeutics LLC., Verity Pharmaceuticals, Arbor Pharmaceuticals, Ferring Pharmaceuticals and Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Uterine Leiomyomata Medication market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
GnRH Agonists
Tranexamic Acid
NSAIDs
Contraceptives (OCs)
Segmentation by application
Oral
Injection
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
AbbVie Inc.
TOLMAR Pharmaceuticals, Inc.
TerSera Therapeutics LLC.
Verity Pharmaceuticals
Arbor Pharmaceuticals
Ferring Pharmaceuticals
Pfizer
Key Questions Addressed in this Report
What is the 10-year outlook for the global Uterine Leiomyomata Medication market?
What factors are driving Uterine Leiomyomata Medication market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Uterine Leiomyomata Medication market opportunities vary by end market size?
How does Uterine Leiomyomata Medication break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Uterine Leiomyomata Medication Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Uterine Leiomyomata Medication by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Uterine Leiomyomata Medication by Country/Region, 2018, 2022 & 2029
2.2 Uterine Leiomyomata Medication Segment by Type
2.2.1 GnRH Agonists
2.2.2 Tranexamic Acid
2.2.3 NSAIDs
2.2.4 Contraceptives (OCs)
2.3 Uterine Leiomyomata Medication Sales by Type
2.3.1 Global Uterine Leiomyomata Medication Sales Market Share by Type (2018-2023)
2.3.2 Global Uterine Leiomyomata Medication Revenue and Market Share by Type (2018-2023)
2.3.3 Global Uterine Leiomyomata Medication Sale Price by Type (2018-2023)
2.4 Uterine Leiomyomata Medication Segment by Application
2.4.1 Oral
2.4.2 Injection
2.5 Uterine Leiomyomata Medication Sales by Application
2.5.1 Global Uterine Leiomyomata Medication Sale Market Share by Application (2018-2023)
2.5.2 Global Uterine Leiomyomata Medication Revenue and Market Share by Application (2018-2023)
2.5.3 Global Uterine Leiomyomata Medication Sale Price by Application (2018-2023)
3 Global Uterine Leiomyomata Medication by Company
3.1 Global Uterine Leiomyomata Medication Breakdown Data by Company
3.1.1 Global Uterine Leiomyomata Medication Annual Sales by Company (2018-2023)
3.1.2 Global Uterine Leiomyomata Medication Sales Market Share by Company (2018-2023)
3.2 Global Uterine Leiomyomata Medication Annual Revenue by Company (2018-2023)
3.2.1 Global Uterine Leiomyomata Medication Revenue by Company (2018-2023)
3.2.2 Global Uterine Leiomyomata Medication Revenue Market Share by Company (2018-2023)
3.3 Global Uterine Leiomyomata Medication Sale Price by Company
3.4 Key Manufacturers Uterine Leiomyomata Medication Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Uterine Leiomyomata Medication Product Location Distribution
3.4.2 Players Uterine Leiomyomata Medication Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Uterine Leiomyomata Medication by Geographic Region
4.1 World Historic Uterine Leiomyomata Medication Market Size by Geographic Region (2018-2023)
4.1.1 Global Uterine Leiomyomata Medication Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Uterine Leiomyomata Medication Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Uterine Leiomyomata Medication Market Size by Country/Region (2018-2023)
4.2.1 Global Uterine Leiomyomata Medication Annual Sales by Country/Region (2018-2023)
4.2.2 Global Uterine Leiomyomata Medication Annual Revenue by Country/Region (2018-2023)
4.3 Americas Uterine Leiomyomata Medication Sales Growth
4.4 APAC Uterine Leiomyomata Medication Sales Growth
4.5 Europe Uterine Leiomyomata Medication Sales Growth
4.6 Middle East & Africa Uterine Leiomyomata Medication Sales Growth
5 Americas
5.1 Americas Uterine Leiomyomata Medication Sales by Country
5.1.1 Americas Uterine Leiomyomata Medication Sales by Country (2018-2023)
5.1.2 Americas Uterine Leiomyomata Medication Revenue by Country (2018-2023)
5.2 Americas Uterine Leiomyomata Medication Sales by Type
5.3 Americas Uterine Leiomyomata Medication Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Uterine Leiomyomata Medication Sales by Region
6.1.1 APAC Uterine Leiomyomata Medication Sales by Region (2018-2023)
6.1.2 APAC Uterine Leiomyomata Medication Revenue by Region (2018-2023)
6.2 APAC Uterine Leiomyomata Medication Sales by Type
6.3 APAC Uterine Leiomyomata Medication Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Uterine Leiomyomata Medication by Country
7.1.1 Europe Uterine Leiomyomata Medication Sales by Country (2018-2023)
7.1.2 Europe Uterine Leiomyomata Medication Revenue by Country (2018-2023)
7.2 Europe Uterine Leiomyomata Medication Sales by Type
7.3 Europe Uterine Leiomyomata Medication Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Uterine Leiomyomata Medication by Country
8.1.1 Middle East & Africa Uterine Leiomyomata Medication Sales by Country (2018-2023)
8.1.2 Middle East & Africa Uterine Leiomyomata Medication Revenue by Country (2018-2023)
8.2 Middle East & Africa Uterine Leiomyomata Medication Sales by Type
8.3 Middle East & Africa Uterine Leiomyomata Medication Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Uterine Leiomyomata Medication
10.3 Manufacturing Process Analysis of Uterine Leiomyomata Medication
10.4 Industry Chain Structure of Uterine Leiomyomata Medication
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Uterine Leiomyomata Medication Distributors
11.3 Uterine Leiomyomata Medication Customer
12 World Forecast Review for Uterine Leiomyomata Medication by Geographic Region
12.1 Global Uterine Leiomyomata Medication Market Size Forecast by Region
12.1.1 Global Uterine Leiomyomata Medication Forecast by Region (2024-2029)
12.1.2 Global Uterine Leiomyomata Medication Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Uterine Leiomyomata Medication Forecast by Type
12.7 Global Uterine Leiomyomata Medication Forecast by Application
13 Key Players Analysis
13.1 AbbVie Inc.
13.1.1 AbbVie Inc. Company Information
13.1.2 AbbVie Inc. Uterine Leiomyomata Medication Product Portfolios and Specifications
13.1.3 AbbVie Inc. Uterine Leiomyomata Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 AbbVie Inc. Main Business Overview
13.1.5 AbbVie Inc. Latest Developments
13.2 TOLMAR Pharmaceuticals, Inc.
13.2.1 TOLMAR Pharmaceuticals, Inc. Company Information
13.2.2 TOLMAR Pharmaceuticals, Inc. Uterine Leiomyomata Medication Product Portfolios and Specifications
13.2.3 TOLMAR Pharmaceuticals, Inc. Uterine Leiomyomata Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 TOLMAR Pharmaceuticals, Inc. Main Business Overview
13.2.5 TOLMAR Pharmaceuticals, Inc. Latest Developments
13.3 TerSera Therapeutics LLC.
13.3.1 TerSera Therapeutics LLC. Company Information
13.3.2 TerSera Therapeutics LLC. Uterine Leiomyomata Medication Product Portfolios and Specifications
13.3.3 TerSera Therapeutics LLC. Uterine Leiomyomata Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 TerSera Therapeutics LLC. Main Business Overview
13.3.5 TerSera Therapeutics LLC. Latest Developments
13.4 Verity Pharmaceuticals
13.4.1 Verity Pharmaceuticals Company Information
13.4.2 Verity Pharmaceuticals Uterine Leiomyomata Medication Product Portfolios and Specifications
13.4.3 Verity Pharmaceuticals Uterine Leiomyomata Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Verity Pharmaceuticals Main Business Overview
13.4.5 Verity Pharmaceuticals Latest Developments
13.5 Arbor Pharmaceuticals
13.5.1 Arbor Pharmaceuticals Company Information
13.5.2 Arbor Pharmaceuticals Uterine Leiomyomata Medication Product Portfolios and Specifications
13.5.3 Arbor Pharmaceuticals Uterine Leiomyomata Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Arbor Pharmaceuticals Main Business Overview
13.5.5 Arbor Pharmaceuticals Latest Developments
13.6 Ferring Pharmaceuticals
13.6.1 Ferring Pharmaceuticals Company Information
13.6.2 Ferring Pharmaceuticals Uterine Leiomyomata Medication Product Portfolios and Specifications
13.6.3 Ferring Pharmaceuticals Uterine Leiomyomata Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Ferring Pharmaceuticals Main Business Overview
13.6.5 Ferring Pharmaceuticals Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Uterine Leiomyomata Medication Product Portfolios and Specifications
13.7.3 Pfizer Uterine Leiomyomata Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Uterine Leiomyomata Medication Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Uterine Leiomyomata Medication Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of GnRH Agonists
Table 4. Major Players of Tranexamic Acid
Table 5. Major Players of NSAIDs
Table 6. Major Players of Contraceptives (OCs)
Table 7. Global Uterine Leiomyomata Medication Sales by Type (2018-2023) & (Kiloton)
Table 8. Global Uterine Leiomyomata Medication Sales Market Share by Type (2018-2023)
Table 9. Global Uterine Leiomyomata Medication Revenue by Type (2018-2023) & ($ million)
Table 10. Global Uterine Leiomyomata Medication Revenue Market Share by Type (2018-2023)
Table 11. Global Uterine Leiomyomata Medication Sale Price by Type (2018-2023) & (US$/Ton)
Table 12. Global Uterine Leiomyomata Medication Sales by Application (2018-2023) & (Kiloton)
Table 13. Global Uterine Leiomyomata Medication Sales Market Share by Application (2018-2023)
Table 14. Global Uterine Leiomyomata Medication Revenue by Application (2018-2023)
Table 15. Global Uterine Leiomyomata Medication Revenue Market Share by Application (2018-2023)
Table 16. Global Uterine Leiomyomata Medication Sale Price by Application (2018-2023) & (US$/Ton)
Table 17. Global Uterine Leiomyomata Medication Sales by Company (2018-2023) & (Kiloton)
Table 18. Global Uterine Leiomyomata Medication Sales Market Share by Company (2018-2023)
Table 19. Global Uterine Leiomyomata Medication Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Uterine Leiomyomata Medication Revenue Market Share by Company (2018-2023)
Table 21. Global Uterine Leiomyomata Medication Sale Price by Company (2018-2023) & (US$/Ton)
Table 22. Key Manufacturers Uterine Leiomyomata Medication Producing Area Distribution and Sales Area
Table 23. Players Uterine Leiomyomata Medication Products Offered
Table 24. Uterine Leiomyomata Medication Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Uterine Leiomyomata Medication Sales by Geographic Region (2018-2023) & (Kiloton)
Table 28. Global Uterine Leiomyomata Medication Sales Market Share Geographic Region (2018-2023)
Table 29. Global Uterine Leiomyomata Medication Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Uterine Leiomyomata Medication Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Uterine Leiomyomata Medication Sales by Country/Region (2018-2023) & (Kiloton)
Table 32. Global Uterine Leiomyomata Medication Sales Market Share by Country/Region (2018-2023)
Table 33. Global Uterine Leiomyomata Medication Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Uterine Leiomyomata Medication Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Uterine Leiomyomata Medication Sales by Country (2018-2023) & (Kiloton)
Table 36. Americas Uterine Leiomyomata Medication Sales Market Share by Country (2018-2023)
Table 37. Americas Uterine Leiomyomata Medication Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Uterine Leiomyomata Medication Revenue Market Share by Country (2018-2023)
Table 39. Americas Uterine Leiomyomata Medication Sales by Type (2018-2023) & (Kiloton)
Table 40. Americas Uterine Leiomyomata Medication Sales by Application (2018-2023) & (Kiloton)
Table 41. APAC Uterine Leiomyomata Medication Sales by Region (2018-2023) & (Kiloton)
Table 42. APAC Uterine Leiomyomata Medication Sales Market Share by Region (2018-2023)
Table 43. APAC Uterine Leiomyomata Medication Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Uterine Leiomyomata Medication Revenue Market Share by Region (2018-2023)
Table 45. APAC Uterine Leiomyomata Medication Sales by Type (2018-2023) & (Kiloton)
Table 46. APAC Uterine Leiomyomata Medication Sales by Application (2018-2023) & (Kiloton)
Table 47. Europe Uterine Leiomyomata Medication Sales by Country (2018-2023) & (Kiloton)
Table 48. Europe Uterine Leiomyomata Medication Sales Market Share by Country (2018-2023)
Table 49. Europe Uterine Leiomyomata Medication Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Uterine Leiomyomata Medication Revenue Market Share by Country (2018-2023)
Table 51. Europe Uterine Leiomyomata Medication Sales by Type (2018-2023) & (Kiloton)
Table 52. Europe Uterine Leiomyomata Medication Sales by Application (2018-2023) & (Kiloton)
Table 53. Middle East & Africa Uterine Leiomyomata Medication Sales by Country (2018-2023) & (Kiloton)
Table 54. Middle East & Africa Uterine Leiomyomata Medication Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Uterine Leiomyomata Medication Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Uterine Leiomyomata Medication Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Uterine Leiomyomata Medication Sales by Type (2018-2023) & (Kiloton)
Table 58. Middle East & Africa Uterine Leiomyomata Medication Sales by Application (2018-2023) & (Kiloton)
Table 59. Key Market Drivers & Growth Opportunities of Uterine Leiomyomata Medication
Table 60. Key Market Challenges & Risks of Uterine Leiomyomata Medication
Table 61. Key Industry Trends of Uterine Leiomyomata Medication
Table 62. Uterine Leiomyomata Medication Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Uterine Leiomyomata Medication Distributors List
Table 65. Uterine Leiomyomata Medication Customer List
Table 66. Global Uterine Leiomyomata Medication Sales Forecast by Region (2024-2029) & (Kiloton)
Table 67. Global Uterine Leiomyomata Medication Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Uterine Leiomyomata Medication Sales Forecast by Country (2024-2029) & (Kiloton)
Table 69. Americas Uterine Leiomyomata Medication Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Uterine Leiomyomata Medication Sales Forecast by Region (2024-2029) & (Kiloton)
Table 71. APAC Uterine Leiomyomata Medication Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Uterine Leiomyomata Medication Sales Forecast by Country (2024-2029) & (Kiloton)
Table 73. Europe Uterine Leiomyomata Medication Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Uterine Leiomyomata Medication Sales Forecast by Country (2024-2029) & (Kiloton)
Table 75. Middle East & Africa Uterine Leiomyomata Medication Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Uterine Leiomyomata Medication Sales Forecast by Type (2024-2029) & (Kiloton)
Table 77. Global Uterine Leiomyomata Medication Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Uterine Leiomyomata Medication Sales Forecast by Application (2024-2029) & (Kiloton)
Table 79. Global Uterine Leiomyomata Medication Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. AbbVie Inc. Basic Information, Uterine Leiomyomata Medication Manufacturing Base, Sales Area and Its Competitors
Table 81. AbbVie Inc. Uterine Leiomyomata Medication Product Portfolios and Specifications
Table 82. AbbVie Inc. Uterine Leiomyomata Medication Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 83. AbbVie Inc. Main Business
Table 84. AbbVie Inc. Latest Developments
Table 85. TOLMAR Pharmaceuticals, Inc. Basic Information, Uterine Leiomyomata Medication Manufacturing Base, Sales Area and Its Competitors
Table 86. TOLMAR Pharmaceuticals, Inc. Uterine Leiomyomata Medication Product Portfolios and Specifications
Table 87. TOLMAR Pharmaceuticals, Inc. Uterine Leiomyomata Medication Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 88. TOLMAR Pharmaceuticals, Inc. Main Business
Table 89. TOLMAR Pharmaceuticals, Inc. Latest Developments
Table 90. TerSera Therapeutics LLC. Basic Information, Uterine Leiomyomata Medication Manufacturing Base, Sales Area and Its Competitors
Table 91. TerSera Therapeutics LLC. Uterine Leiomyomata Medication Product Portfolios and Specifications
Table 92. TerSera Therapeutics LLC. Uterine Leiomyomata Medication Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 93. TerSera Therapeutics LLC. Main Business
Table 94. TerSera Therapeutics LLC. Latest Developments
Table 95. Verity Pharmaceuticals Basic Information, Uterine Leiomyomata Medication Manufacturing Base, Sales Area and Its Competitors
Table 96. Verity Pharmaceuticals Uterine Leiomyomata Medication Product Portfolios and Specifications
Table 97. Verity Pharmaceuticals Uterine Leiomyomata Medication Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 98. Verity Pharmaceuticals Main Business
Table 99. Verity Pharmaceuticals Latest Developments
Table 100. Arbor Pharmaceuticals Basic Information, Uterine Leiomyomata Medication Manufacturing Base, Sales Area and Its Competitors
Table 101. Arbor Pharmaceuticals Uterine Leiomyomata Medication Product Portfolios and Specifications
Table 102. Arbor Pharmaceuticals Uterine Leiomyomata Medication Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 103. Arbor Pharmaceuticals Main Business
Table 104. Arbor Pharmaceuticals Latest Developments
Table 105. Ferring Pharmaceuticals Basic Information, Uterine Leiomyomata Medication Manufacturing Base, Sales Area and Its Competitors
Table 106. Ferring Pharmaceuticals Uterine Leiomyomata Medication Product Portfolios and Specifications
Table 107. Ferring Pharmaceuticals Uterine Leiomyomata Medication Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 108. Ferring Pharmaceuticals Main Business
Table 109. Ferring Pharmaceuticals Latest Developments
Table 110. Pfizer Basic Information, Uterine Leiomyomata Medication Manufacturing Base, Sales Area and Its Competitors
Table 111. Pfizer Uterine Leiomyomata Medication Product Portfolios and Specifications
Table 112. Pfizer Uterine Leiomyomata Medication Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 113. Pfizer Main Business
Table 114. Pfizer Latest Developments
List of Figures
Figure 1. Picture of Uterine Leiomyomata Medication
Figure 2. Uterine Leiomyomata Medication Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Uterine Leiomyomata Medication Sales Growth Rate 2018-2029 (Kiloton)
Figure 7. Global Uterine Leiomyomata Medication Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Uterine Leiomyomata Medication Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of GnRH Agonists
Figure 10. Product Picture of Tranexamic Acid
Figure 11. Product Picture of NSAIDs
Figure 12. Product Picture of Contraceptives (OCs)
Figure 13. Global Uterine Leiomyomata Medication Sales Market Share by Type in 2022
Figure 14. Global Uterine Leiomyomata Medication Revenue Market Share by Type (2018-2023)
Figure 15. Uterine Leiomyomata Medication Consumed in Oral
Figure 16. Global Uterine Leiomyomata Medication Market: Oral (2018-2023) & (Kiloton)
Figure 17. Uterine Leiomyomata Medication Consumed in Injection
Figure 18. Global Uterine Leiomyomata Medication Market: Injection (2018-2023) & (Kiloton)
Figure 19. Global Uterine Leiomyomata Medication Sales Market Share by Application (2022)
Figure 20. Global Uterine Leiomyomata Medication Revenue Market Share by Application in 2022
Figure 21. Uterine Leiomyomata Medication Sales Market by Company in 2022 (Kiloton)
Figure 22. Global Uterine Leiomyomata Medication Sales Market Share by Company in 2022
Figure 23. Uterine Leiomyomata Medication Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Uterine Leiomyomata Medication Revenue Market Share by Company in 2022
Figure 25. Global Uterine Leiomyomata Medication Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Uterine Leiomyomata Medication Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Uterine Leiomyomata Medication Sales 2018-2023 (Kiloton)
Figure 28. Americas Uterine Leiomyomata Medication Revenue 2018-2023 ($ Millions)
Figure 29. APAC Uterine Leiomyomata Medication Sales 2018-2023 (Kiloton)
Figure 30. APAC Uterine Leiomyomata Medication Revenue 2018-2023 ($ Millions)
Figure 31. Europe Uterine Leiomyomata Medication Sales 2018-2023 (Kiloton)
Figure 32. Europe Uterine Leiomyomata Medication Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Uterine Leiomyomata Medication Sales 2018-2023 (Kiloton)
Figure 34. Middle East & Africa Uterine Leiomyomata Medication Revenue 2018-2023 ($ Millions)
Figure 35. Americas Uterine Leiomyomata Medication Sales Market Share by Country in 2022
Figure 36. Americas Uterine Leiomyomata Medication Revenue Market Share by Country in 2022
Figure 37. Americas Uterine Leiomyomata Medication Sales Market Share by Type (2018-2023)
Figure 38. Americas Uterine Leiomyomata Medication Sales Market Share by Application (2018-2023)
Figure 39. United States Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Uterine Leiomyomata Medication Sales Market Share by Region in 2022
Figure 44. APAC Uterine Leiomyomata Medication Revenue Market Share by Regions in 2022
Figure 45. APAC Uterine Leiomyomata Medication Sales Market Share by Type (2018-2023)
Figure 46. APAC Uterine Leiomyomata Medication Sales Market Share by Application (2018-2023)
Figure 47. China Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Uterine Leiomyomata Medication Sales Market Share by Country in 2022
Figure 55. Europe Uterine Leiomyomata Medication Revenue Market Share by Country in 2022
Figure 56. Europe Uterine Leiomyomata Medication Sales Market Share by Type (2018-2023)
Figure 57. Europe Uterine Leiomyomata Medication Sales Market Share by Application (2018-2023)
Figure 58. Germany Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Uterine Leiomyomata Medication Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Uterine Leiomyomata Medication Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Uterine Leiomyomata Medication Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Uterine Leiomyomata Medication Sales Market Share by Application (2018-2023)
Figure 67. Egypt Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Uterine Leiomyomata Medication Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Uterine Leiomyomata Medication in 2022
Figure 73. Manufacturing Process Analysis of Uterine Leiomyomata Medication
Figure 74. Industry Chain Structure of Uterine Leiomyomata Medication
Figure 75. Channels of Distribution
Figure 76. Global Uterine Leiomyomata Medication Sales Market Forecast by Region (2024-2029)
Figure 77. Global Uterine Leiomyomata Medication Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Uterine Leiomyomata Medication Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Uterine Leiomyomata Medication Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Uterine Leiomyomata Medication Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Uterine Leiomyomata Medication Revenue Market Share Forecast by Application (2024-2029)

※参考情報

子宮平滑筋腫（Uterine Leiomyomata）は、女性の子宮に発生する良性の腫瘍で、特に中年女性に多く見られます。これらの腫瘍は、筋肉と結合組織から構成されており、通常は痛みを伴わないことが多いですが、大きくなると周囲の組織を圧迫し、さまざまな症状を引き起こすことがあります。これには、月経過多、腰痛、圧迫感、不妊症などが含まれます。子宮平滑筋腫の治療には、外科手術と薬物療法がありますが、近年、薬物療法の選択肢が増えています。

子宮平滑筋腫治療薬の定義は、平滑筋腫の症状を軽減し、腫瘍の成長を制御することを目的とした薬物を指します。これらの薬は、ホルモンの影響を受けやすい平滑筋腫の性質を利用して、治療効果を発揮します。特にエストロゲンやプロゲステロンによって刺激され、このホルモンの作用を抑えることが治療の基本になります。

子宮平滑筋腫治療薬には、主に以下の種類があります。まず、ホルモン療法が挙げられます。この中には、経口避妊薬やホルモン補充療法が含まれ、エストロゲンとプロゲステロンのバランスを調整することで、筋腫の成長を抑制します。また、GnRHアゴニストという薬剤があり、これにより生理的に卵巣機能を抑制し、更年期状態を一時的に作り出すことで腫瘍の大きさを縮小させる効果があります。

一方、最近の研究では新たな治療薬の選択肢として、筋腫に特異的に作用する薬剤が開発されています。これには、ルシプロストン（ulipristal acetate）のような選択的プロゲステロン受容体調節薬（SPRM）が含まれます。これらの薬剤は、プロゲステロン受容体に結合することで筋腫の成長を抑え、症状を軽減します。これらの薬は、手術を行う前の準備として、または手術が適さない患者に対しても用いられることがあります。

子宮平滑筋腫治療薬の主な用途は、筋腫によって引き起こされる症状の管理です。薬剤による治療は患者のQOL（Quality of Life）を改善し、症状の緩和を図るための重要な手段とされています。また、薬物療法は手術治療を選択する際の前処置としても使用されることがあり、手術のリスクを減少させ、術後の回復を助ける役割も果たします。

さらに、薬剤だけでは不十分な場合には、関連技術や手術療法も考慮されます。例えば、MRIガイド下子宮筋腫核出術（MRgFUS）や子宮動脈塞栓術（UAE）といった非侵襲的な治療法も広く用いられています。これらの技術は、見逃しやすい筋腫の特定や、その後の治療においても便利です。特にMRIガイド下手法は、腫瘍の位置や大きさを正確に把握できるため、効果的な治療が行えます。

子宮平滑筋腫治療薬は、安全性と副作用の観点からも注意が必要です。ホルモン療法では、血栓症や肝機能障害、骨密度の低下などのリスクが考慮されなければなりません。また、ルシプロストンなどの新しい薬剤についても、副作用や治療効果の長期的な観察が重要です。患者一人ひとりの状態や希望に応じて、適切な治療法の選択が求められます。

このように、子宮平滑筋腫治療薬は、治療法の選択肢を広げる役割を果たしており、患者の健康と生活の質の向上に大きく貢献しています。医療の進歩によって、今後も新しい治療法や薬剤が登場し、より効果的な治療が提供されることが期待されます。患者の症状や背景に応じた個別化された治療が求められる中、医療従事者が適切な選択を行うための知識と技術の向上が必要です。これからも、研究が進むことにより、より多くの選択肢が生まれることを望んでいます。


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界の子宮平滑筋腫治療薬市場予測 2023年-2029年(Global Uterine Leiomyomata Medication Market Growth 2023-2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 薬用冷蔵庫のグローバル市場展望 2023年-2029年：卓上型、キャビネット型
  • 血友病治療薬のグローバル市場展望 2023年-2029年：血液製品、遺伝子組み換え製品
  • 子宮ポリープ鉗子の世界市場見通し2023年-2029年
  • 子宮内避妊具の世界市場見通し2023年-2029年
  • 子宮腔型子宮内避妊器具のグローバル市場2025年：企業・地域・タイプ・用途別分析

    • ◆H&Iグローバルリサーチのお客様（例）◆